Download PDF
Thromb Haemost
DOI: 10.1055/a-2510-6147
Blood Cells, Inflammation and Infection

Association of Specific Antiphospholipid Antibodies to Platelet Count and Thrombocytopenia

Katharina Griem
1   Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Mainz, Mainz, Germany
,
Tanja Falter
1   Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Mainz, Mainz, Germany
,
Anne Hollerbach
1   Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Mainz, Mainz, Germany
,
Kerstin Jurk 
2   Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany
,
Brahim Aboulmaouahib
3   Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center Mainz, Mainz, Germany
,
Julia Weinmann-Menke
4   Department of Medicine I, University Medical Center Mainz, Mainz, Germany
,
Nadine Müller-Calleja
1   Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Mainz, Mainz, Germany
2   Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany
,
Karl J. Lackner
1   Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Mainz, Mainz, Germany
› Author Affiliations Funding This study was supported in part by the German Federal Ministry of Education and Research (BMBF 01EO1003).
› Further Information
Also available at
    Permissions and Reprints


Abstract

Background Thrombocytopenia is one of the most common manifestations of the antiphospholipid syndrome (APS). However, its causes are still poorly defined. We have shown recently that antiphospholipid antibodies (aPL) directed against β2-glycoprotein I (β2GPI) of the IgG isotype induced platelet activation and aggregation while aPL directed against cardiolipin and anti-β2GPI IgM had no effect. Since platelet activation by anti-β2GPI might lead to platelet consumption and lower platelet count or overt thrombocytopenia, we analyzed the association of aPL with platelet count.

Material and Methods Data of consecutive patients with test orders for anticardiolipin IgG/IgM and anti-β2GPI IgG/IgM and full blood count in our laboratory from August 2015 to April 2019 were analyzed.

Results We identified 2,815 individual patients (mean age 45.7 years; 71.1% women) with complete data on aPL and platelet count, of which 445 individuals (mean age 41.0 years; 75.3% women) showed increased aPL titers. Patients with anti-β2GPI of the IgG isotype had significantly lower platelet count (220 ± 84 versus 264 ± 90 G/L, p < 0.0001) and higher frequency of thrombocytopenia (platelet count <100 G/L; 12.2% versus 2.4%, p < 0.005) than patients negative for all four aPL. These differences could not be explained by comorbidities or medications. Neither anticardiolipin IgG nor aPL of the IgM isotype was associated with lower platelet count or thrombocytopenia.

Conclusion The exclusive association of anti-β2GPI IgG aPL with low platelet count coincides with its unique ability to activate platelets and induce aggregation in vitro. This supports the hypothesis that anti-β2GPI IgG aPL may induce thrombocytopenia by chronic platelet consumption in vivo.

Keywords

antiphospholipid antibodies - platelet count - thrombocytopenia

Authors' Contribution

K.G. included data from medical documentation, reviewed the data, and wrote the manuscript (medical dissertation); J.W.M. provided critical patient data; B.A. reviewed the statistics; A.H. reviewed the data and wrote the manuscript; T.F., J.W.M., N.M.-C., and K.J. reviewed the data and the manuscript; K.J.L. designed the study, reviewed the data, and wrote the manuscript. The authors are responsible for the contents of this publication.


Supplementary Material



Publication History

Received: 13 August 2024

Accepted: 06 January 2025

Accepted Manuscript online:
07 January 2025

Article published online:
27 January 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Cervera R, Serrano R, Pons-Estel GJ. et al; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74 (06) 1011-1018
    CrossrefPubMedSearch in Google Scholar
  • 2 Barbhaiya M, Zuily S, Naden R. et al; ACR/EULAR APS Classification Criteria Collaborators. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis 2023; 82 (10) 1258-1270
    CrossrefPubMedSearch in Google Scholar
  • 3 Schreiber K, Sciascia S, de Groot PG. et al. Antiphospholipid syndrome. Nat Rev Dis Primers 2018; 4: 17103
    CrossrefPubMedSearch in Google Scholar
  • 4 Artim-Esen B, Diz-Küçükkaya R, İnanç M.. The significance and management of thrombocytopenia in antiphospholipid syndrome. Curr Rheumatol Rep 2015; 17 (03) 14
    CrossrefPubMedSearch in Google Scholar
  • 5 Vreede AP, Bockenstedt PL, McCune WJ, Knight JS. Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome. Curr Opin Rheumatol 2019; 31 (03) 231-240
    CrossrefPubMedSearch in Google Scholar
  • 6 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
    CrossrefPubMedSearch in Google Scholar
  • 7 Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7 (06) 330-339
    CrossrefPubMedSearch in Google Scholar
  • 8 de Groot PG. The antiphospholipid syndrome finally fathomed?. Blood 2018; 131 (19) 2091-2092
    CrossrefPubMedSearch in Google Scholar
  • 9 Redecha P, Tilley R, Tencati M. et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110 (07) 2423-2431
    CrossrefPubMedSearch in Google Scholar
  • 10 Prinz N, Clemens N, Strand D. et al. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells. Blood 2011; 118 (08) 2322-2332
    CrossrefPubMedSearch in Google Scholar
  • 11 Prinz N, Clemens N, Canisius A. et al. Lessons from the antiphospholipid syndrome. Endosomal NADPH-oxidase is critical for induction of the tissue factor gene in monocytes and endothelial cells. Thromb Haemost 2013; 109: 525-531
    Thieme ConnectPubMedSearch in Google Scholar
  • 12 Manukyan D, Müller-Calleja N, Jäckel S. et al. Cofactor-independent human antiphospholipid antibodies induce venous thrombosis in mice. J Thromb Haemost 2016; 14 (05) 1011-1020
    CrossrefPubMedSearch in Google Scholar
  • 13 Müller-Calleja N, Ritter S, Hollerbach A, Falter T, Lackner KJ, Ruf W. Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies. Blood Adv 2018; 2 (09) 979-986
    CrossrefPubMedSearch in Google Scholar
  • 14 Lackner KJ, Müller-Calleja N. Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma. J Thromb Haemost 2016; 14 (06) 1117-1120
    CrossrefPubMedSearch in Google Scholar
  • 15 Müller-Calleja N, Köhler A, Siebald B. et al. Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications for the antiphospholipid syndrome. Thromb Haemost 2015; 113 (05) 1071-1083
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Müller-Calleja N, Hollerbach A, Royce J. et al. Lipid presentation by the protein C receptor links coagulation with autoimmunity. Science 2021; 371 (6534) eabc0956
    CrossrefPubMedSearch in Google Scholar
  • 17 Müller-Calleja N, Hollerbach A, Häuser F. et al. Antiphospholipid antibody induced cellular responses depend on epitope specificity—implications for treatment of APS. J Thromb Haemost 2017; 15: 2367-2376
    CrossrefPubMedSearch in Google Scholar
  • 18 Hollerbach A, Müller-Calleja N, Ritter S. et al. Platelet activation by antiphospholipid antibodies depends on epitope specificity and is prevented by mTOR inhibitors. Thromb Haemost 2019; 119 (07) 1147-1153
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Manukyan D, Rossmann H, Schulz A. et al. Distribution of antiphospholipid antibodies in a large population-based German cohort. Clin Chem Lab Med 2016; 54 (10) 1663-1670
    CrossrefPubMedSearch in Google Scholar
  • 20 Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17 (08) 857-872
    CrossrefPubMedSearch in Google Scholar
  • 21 Urbanus RT, Derksen RH, de Groot PG. Platelets and the antiphospholipid syndrome. Lupus 2008; 17 (10) 888-894
    CrossrefPubMedSearch in Google Scholar
  • 22 Baroni G, Banzato A, Bison E, Denas G, Zoppellaro G, Pengo V. The role of platelets in antiphospholipid syndrome. Platelets 2017; 28 (08) 762-766
    CrossrefPubMedSearch in Google Scholar
  • 23 Fanelli A, Bergamini C, Rapi S. et al. Flow cytometric detection of circulating activated platelets in primary antiphospholipid syndrome. Correlation with thrombocytopenia and anticardiolipin antibodies. Lupus 1997; 6 (03) 261-267
    CrossrefPubMedSearch in Google Scholar
  • 24 Wiener MH, Burke M, Fried M, Yust I. Thromboagglutination by anticardiolipin antibody complex in the antiphospholipid syndrome: a possible mechanism of immune-mediated thrombosis. Thromb Res 2001; 103 (03) 193-199
    CrossrefPubMedSearch in Google Scholar
  • 25 Müller-Calleja N, Ruf W, Lackner KJ. Lipid-binding antiphospholipid antibodies: significance for pathophysiology and diagnosis of the antiphospholipid syndrome. Crit Rev Clin Lab Sci 2024; 61 (05) 370-387
    CrossrefPubMedSearch in Google Scholar